CPI-200 / Coordination Pharma - LARVOL DELTA

Study of CPI-200 in Patients With Advanced Tumors (clinicaltrials.gov) - P1 | N=17 | Completed | Sponsor: Coordination Pharmaceuticals, Inc. | Recruiting ➔ Completed | N=27 ➔ 17 | Trial completion date: Dec 2022 ➔ Feb 2022 | Trial primary completion date: Jun 2022 ➔ Feb 2022

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

Study of CPI-200 in Patients With Advanced Tumors (clinicaltrials.gov) - P1; N=27; Recruiting; Sponsor: Coordination Pharmaceuticals, Inc.; Trial completion date: Jun 2022 ➔ Dec 2022; Trial primary completion date: Dec 2021 ➔ Jun 2022

Clinical • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

Study of CPI-200 in Patients With Advanced Tumors (clinicaltrials.gov) - P1; N=27; Recruiting; Sponsor: Coordination Pharmaceuticals, Inc.; Trial completion date: Jun 2021 ➔ Jun 2022; Trial primary completion date: Dec 2020 ➔ Dec 2021

Clinical • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

Coordination Pharmaceuticals announces enrollment of the first patient in phase 1 study of CPI-200 in patients with advanced tumors (PRNewswire) - "Coordination Pharmaceuticals Inc. (CPI), a privately-held oncology drug development company today announced that the first patient has been dosed in a Phase 1 study of CPI-200 in patients with advanced tumors...'We expect that this study will generate important insights about the safety and pharmacokinetics of CPI-200 and the synergistic actions of the two NMEs on patients' tumors which no longer respond to standard therapies,' said Everett Vokes, M.D...The Phase 1 study is a prospective, open-label, single-arm, non-randomized study of CPI-200 in patients with advanced tumors. The primary objectives in the study include determining maximum tolerated dose (MTD), pharmacokinetics and preliminary anti-tumor activity of CPI-200."

Enrollment open

Study of CPI-200 in Patients With Advanced Tumors (clinicaltrials.gov) - P1; N=27; Recruiting; Sponsor: Coordination Pharmaceuticals, Inc.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open